{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:57:25Z","timestamp":1795021045173,"version":"4.10.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Randomized, placebo-controlled clinical trials (RCTs) that include analytical treatment interruptions (ATI) are conducted to test the efficacy of HIV cure strategies. Two independent RCTs, AELIX-002 and AELIX-003, evaluated the HTI immunogen-based vaccines alone or combined with the TLR7 agonist vesatolimod in early-treated people with HIV (etPWH). These studies individually demonstrated that higher levels of vaccine-induced HTI-specific T-cell responses were associated with extended time off antiretroviral therapy (ART) during a 24-week ATI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pooled analysis of both RCTs including the individual data of a total of 88 participants. The association between clinical, immunogenicity and viral data and rebound outcomes during the ATI was evaluated using logistic regression and receiver operating characteristic (ROC) analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identify an HTI-specific threshold of 835 spot-forming cells\/10\n                      <jats:sup>6<\/jats:sup>\n                      peripheral blood mononuclear cells as a predictor of delayed and slower viral rebound during ATI. This threshold distinguishes participants who remain off ART for &gt;12 weeks, with 58% sensitivity, 85% specificity, 75% positive and 73% negative predictive value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings confirm that HTI-specific T-cell magnitude at ATI initiation is the strongest predictor of ATI outcomes observed in AELIX002\/003 studies and that a threshold of vaccine-induced HTI-specific T-cell responses can be used as futility criteria before ATI and\/or guide participant selection in future HTI-based HIV cure trials aimed at achieving therapy-free remission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-025-01266-y","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T08:46:09Z","timestamp":1765183569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-9314","authenticated-orcid":false,"given":"Lucia","family":"Bail\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-8634","authenticated-orcid":false,"given":"Yovaninna","family":"Alarc\u00f3n-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuska","family":"Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-0208","authenticated-orcid":false,"given":"Samandhy","family":"Cede\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-691X","authenticated-orcid":false,"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-1773","authenticated-orcid":false,"given":"Elena","family":"Vendrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"SenGupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romas","family":"Geleziunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie P.","family":"Malice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-5778","authenticated-orcid":false,"given":"Christian","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-407X","authenticated-orcid":false,"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1093\/infdis\/jiz222","volume":"220","author":"DM Margolis","year":"2019","unstructured":"Margolis, D. M. & Deeks, S. G. How unavoidable are analytical treatment interruptions in HIV cure-related studies? J. Infect. Dis. 220, S24\u2013S26 (2019).","journal-title":"J. Infect. Dis."},{"key":"1266_CR2","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.1.20497","volume":"18","author":"GM Graziani","year":"2015","unstructured":"Graziani, G. M. & Angel, J. B. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J. Int. AIDS Soc. 18, 20497 (2015).","journal-title":"J. Int. AIDS Soc."},{"key":"1266_CR3","doi-asserted-by":"publisher","first-page":"e1006792","DOI":"10.1371\/journal.ppat.1006792","volume":"14","author":"KE Clarridge","year":"2018","unstructured":"Clarridge, K. E. et al. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 14, e1006792 (2018).","journal-title":"PLoS Pathog."},{"key":"1266_CR4","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1097\/QAD.0000000000001560","volume":"31","author":"M Montserrat","year":"2017","unstructured":"Montserrat, M. et al. Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients. AIDS 31, 1895\u20131897 (2017).","journal-title":"AIDS"},{"key":"1266_CR5","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1172\/JCI120194","volume":"128","author":"DB Salantes","year":"2018","unstructured":"Salantes, D. B. et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J. Clin. Invest. 128, 3102\u20133115 (2018).","journal-title":"J. Clin. Invest"},{"key":"1266_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2055-6640(20)30287-9","volume":"3","author":"SA Garner","year":"2017","unstructured":"Garner, S. A. et al. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J. Virus Erad. 3, 82\u201384 (2017).","journal-title":"J. Virus Erad."},{"key":"1266_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13528-8","volume":"22","author":"DM Campbell","year":"2022","unstructured":"Campbell, D. M. et al. \u2018It comes altogether as one:\u2019 perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States. BMC Public Health 22, 1317 (2022).","journal-title":"BMC Public Health"},{"key":"1266_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1089\/aid.2019.0118","volume":"36","author":"JSY Lau","year":"2020","unstructured":"Lau, J. S. Y. et al. Perspectives on analytical treatment interruptions in people living with HIV and their health care providers in the landscape of HIV cure-focused studies. AIDS Res Hum. Retroviruses 36, 260\u2013267 (2020).","journal-title":"AIDS Res Hum. Retroviruses"},{"key":"1266_CR9","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1038\/s41591-022-02060-2","volume":"28","author":"L Bail\u00f3n","year":"2022","unstructured":"Bail\u00f3n, L. et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. Nat. Med. 28, 2611\u20132621 (2022).","journal-title":"Nat. Med."},{"key":"1266_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57284-w","volume":"16","author":"L Bail\u00f3n","year":"2025","unstructured":"Bail\u00f3n, L. et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. Nat. Commun. 16, 2146 (2025).","journal-title":"Nat. Commun."},{"key":"1266_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183952","volume":"135","author":"I Gonz\u00e1lez-Navarro","year":"2024","unstructured":"Gonz\u00e1lez-Navarro, I. et al. Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir. J. Clin. Invest. 135, e183952 (2024).","journal-title":"J. Clin. Invest."},{"key":"1266_CR12","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/jac\/dkz138","volume":"74","author":"A Castagna","year":"2019","unstructured":"Castagna, A. et al. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). J. Antimicrob. Chemother. 74, 2039\u20132046 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"1266_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173864","volume":"9","author":"JZ Li","year":"2024","unstructured":"Li, J. Z. et al. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation. JCI Insight 9, e173864 (2024).","journal-title":"JCI Insight"},{"key":"1266_CR14","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.03821","volume":"3","author":"JP Williams","year":"2014","unstructured":"Williams, J. P. et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife 3, e03821 (2014).","journal-title":"Elife"},{"key":"1266_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/infdis\/jiaf163","volume":"232","author":"V Klastrup","year":"2025","unstructured":"Klastrup, V., Gunst, J. D., Rasmussen, T. A., Tolstrup, M. & S\u00f8gaard, O. S. Factors influencing virologic control during analytical treatment interruptions in HIV cure trials-a pooled analysis of individual-level data. J. Infect. Dis. 232, 69\u201378 (2025).","journal-title":"J. Infect. Dis."},{"key":"1266_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06151-w","volume":"23","author":"MJ Lee","year":"2022","unstructured":"Lee, M. J. et al. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection\u2014study protocol for a two-stage randomised phase II trial. Trials 23, 263 (2022).","journal-title":"Trials"},{"key":"1266_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56116-1","volume":"16","author":"JD Gunst","year":"2025","unstructured":"Gunst, J. D. et al. Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies. Nat. Commun. 16, 906 (2025).","journal-title":"Nat. Commun."},{"key":"1266_CR18","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","volume":"6","author":"B Julg","year":"2019","unstructured":"Julg, B. et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV 6, e259\u2013e268 (2019).","journal-title":"Lancet HIV"},{"key":"1266_CR19","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1093\/infdis\/jiae551","volume":"231","author":"G Magombedze","year":"2025","unstructured":"Magombedze, G. et al. Early viral dynamics predict human immunodeficiency virus posttreatment control after analytic treatment interruption. J. Infect. Dis. 231, e419\u2013e428 (2025).","journal-title":"J. Infect. Dis."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01266-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:41:07Z","timestamp":1767760867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01266-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01266-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6567488\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.B. reports speaker fees from Gilead Sciences and ViiV Healthcare, outside the scope of the submitted work. J.R.A. reports advisory and speaker fees and grant support from ViiV, Janssen, Gilead Sciences, MSD and AELIX Therapeutics. A.C. reports advisory and speaker fees and grant support from Gilead Sciences, Janssen, MSD and ViiV Healthcare. R.P. reports research grants from Merck Sharp & Dohme, ViiV Healthcare, Gilead Sciences and PharmaMar; consultancy fees for Gilead Sciences, Pfizer, Roche Therapeutics, AstraZeneca, Merck Sharp & Dohme, GSK, ViiV Healthcare, Eli Lilly and Company, and PharmaMar; and honoraria from Gilead Sciences, Pfizer, AstraZeneca, Merck Sharp & Dohme and PharmaMar, outside of the submitted work. E.V., D.S., J.J.W., and R.G. are employees and stockholders of Gilead Sciences. I.M. was an employee of AELIX Therapeutics S.L. at the time of the study, and is currently an employee of Orion Biotechnology, and is a consultant for Synklino, outside the scope of the submitted work. C.B., B.M., and A.L.L. are co-inventors of the HTI immunogen (patent application PCT\/EP2013\/051596). C.B., B.M., and I.M. are co-inventors of US patent application no. 62\/935,519 and US patent application no. 62\/851,546, which have relevance to the vaccine regimen used in both studies. C.B. was co-founder, Chief Scientific Officer, and shareholder of AELIX Therapeutics S.L. and serves as an advisor for Tendel Therapies and OmniScope, outside of the submitted work, and reports speaker fees from Gilead Sciences. J.M. has received research funding, consultancy fees and lecture sponsorships from, and has served on advisory boards for, various laboratories (MSD, AbbVie, Boehringer Ingelheim, Gilead Sciences, Viiv Healthcare, Janssen-Cilag and Bristol Myers Squibb). B.M. reports past consultancy personal fees from AELIX Therapeutics S.L., as well as speaker fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare, outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}